These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17673715)

  • 21. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
    Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
    J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular basis of oral hypoglycemic sulfonylurea action].
    Owecki M; Horst-Sikorska W; Sowiński J
    Pol Merkur Lekarski; 2003 Nov; 15(89):445-8. PubMed ID: 14969140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of the glycaemic effects of sulfonylureas.
    Ashcroft FM
    Horm Metab Res; 1996 Sep; 28(9):456-63. PubMed ID: 8911983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced Intracerebral Hemorrhage and Perihematomal Edema Volumes in Diabetics on Sulfonylureas.
    Irvine H; Male S; Robertson J; Bell C; Bentho O; Streib C
    Stroke; 2019 Apr; 50(4):995-998. PubMed ID: 30879436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does inhibiting Sur1 complement rt-PA in cerebral ischemia?
    Simard JM; Geng Z; Silver FL; Sheth KN; Kimberly WT; Stern BJ; Colucci M; Gerzanich V
    Ann N Y Acad Sci; 2012 Sep; 1268():95-107. PubMed ID: 22994227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes.
    Masia R; Koster JC; Tumini S; Chiarelli F; Colombo C; Nichols CG; Barbetti F
    Diabetes; 2007 Feb; 56(2):328-36. PubMed ID: 17259376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulfonylurea receptor 1 in central nervous system injury: a focused review.
    Simard JM; Woo SK; Schwartzbauer GT; Gerzanich V
    J Cereb Blood Flow Metab; 2012 Sep; 32(9):1699-717. PubMed ID: 22714048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KATP channel openers: structure-activity relationships and therapeutic potential.
    Mannhold R
    Med Res Rev; 2004 Mar; 24(2):213-66. PubMed ID: 14705169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of sulfonylurea receptor type 1 subunits of ATP-sensitive potassium channels in myocardial ischemia/reperfusion injury.
    Elrod JW; Harrell M; Flagg TP; Gundewar S; Magnuson MA; Nichols CG; Coetzee WA; Lefer DJ
    Circulation; 2008 Mar; 117(11):1405-13. PubMed ID: 18316485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sulfonylurea receptors].
    Huupponen R
    Duodecim; 1989; 105(19):1578-80. PubMed ID: 2553390
    [No Abstract]   [Full Text] [Related]  

  • 31. Epac2: a sulfonylurea receptor?
    Rehmann H
    Biochem Soc Trans; 2012 Feb; 40(1):6-10. PubMed ID: 22260657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels.
    Ammälä C; Moorhouse A; Gribble F; Ashfield R; Proks P; Smith PA; Sakura H; Coles B; Ashcroft SJ; Ashcroft FM
    Nature; 1996 Feb; 379(6565):545-8. PubMed ID: 8596634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of sulphonylurea derivatives in treatment of diabetes type 2. The role of glimepiride].
    Sieradzki J
    Przegl Lek; 2000; 57 Suppl 4():13-8. PubMed ID: 11293224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new mesangial triumvirate: sulfonylureas, their receptors and endosulfines.
    Yee J; Szamosfalvi B
    Exp Nephrol; 2002; 10(1):1-6. PubMed ID: 11803199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    Sesti G; Laratta E; Cardellini M; Andreozzi F; Del Guerra S; Irace C; Gnasso A; Grupillo M; Lauro R; Hribal ML; Perticone F; Marchetti P
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2334-9. PubMed ID: 16595597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ABCC8 polymorphisms are associated with triglyceride concentration in type 2 diabetics on sulfonylurea therapy.
    Nikolac N; Simundic AM; Saracevic A; Katalinic D
    Genet Test Mol Biomarkers; 2012 Aug; 16(8):924-30. PubMed ID: 22533711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity.
    Nagashima K; Takahashi A; Ikeda H; Hamasaki A; Kuwamura N; Yamada Y; Seino Y
    Diabetes Res Clin Pract; 2004 Dec; 66 Suppl 1():S75-8. PubMed ID: 15563985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia.
    Ortega FJ; Jolkkonen J; Mahy N; Rodríguez MJ
    J Cereb Blood Flow Metab; 2013 Mar; 33(3):356-64. PubMed ID: 23149556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the rat mesangial cell type 2 sulfonylurea receptor.
    Asano K; Cortes P; Garvin JL; Riser BL; Rodríguez-Barbero A; Szamosfalvi B; Yee J
    Kidney Int; 1999 Jun; 55(6):2289-98. PubMed ID: 10354277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of the sulfonylurea receptor (SUR) as the target of diflubenzuron in chitin synthesis inhibition in Drosophila melanogaster and Blattella germanica.
    Abo-Elghar GE; Fujiyoshi P; Matsumura F
    Insect Biochem Mol Biol; 2004 Aug; 34(8):743-52. PubMed ID: 15262279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.